Targeting Galectin-driven Regulatory Circuits in Cancer and Fibrosis

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2023 Feb 9

PMID 36759557

Authors

Karina V Marino

Alejandro J Cagnoni

Diego O Croci

Gabriel A Rabinovich

Affiliations

Soon will be listed here.

Abstract

Galectins are a family of endogenous glycan-binding proteins that have crucial roles in a broad range of physiological and pathological processes. As a group, these proteins use both extracellular and intracellular mechanisms as well as glycan-dependent and independent pathways to reprogramme the fate and function of numerous cell types. Given their multifunctional roles in both tissue fibrosis and cancer, galectins have been identified as potential therapeutic targets for these disorders. Here, we focus on the therapeutic relevance of galectins, particularly galectin 1 (GAL1), GAL3 and GAL9 to tumour progression and fibrotic diseases. We consider an array of galectin-targeted strategies, including small-molecule carbohydrate inhibitors, natural polysaccharides and their derivatives, peptides, peptidomimetics and biological agents (notably, neutralizing monoclonal antibodies and truncated galectins) and discuss their mechanisms of action, selectivity and therapeutic potential in preclinical models of fibrosis and cancer. We also review the results of clinical trials that aim to evaluate the efficacy of galectin inhibitors in patients with idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis and cancer. The rapid pace of glycobiology research, combined with the acute need for drugs to alleviate fibrotic inflammation and overcome resistance to anticancer therapies, will accelerate the translation of anti-galectin therapeutics into clinical practice.

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

Editorial: Galectins and hormones in health and disease.

Troncoso M, Chammas R, Carvalho V, Oliveira F, Villa-Verde D Front Endocrinol (Lausanne). 2025; 16:1545421.

PMID: 39974822 PMC: 11835660. DOI: 10.3389/fendo.2025.1545421.

Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis.

Perera K, Ghumman M, Sorkhdini P, Norbrun C, Negash S, Zhou Y J Mater Chem B. 2025; 13(10):3325-3339.

PMID: 39918485 PMC: 11804936. DOI: 10.1039/d4tb01682c.

Supramolecular discrimination and diagnosis-guided treatment of intracellular bacteria.

Tian J, Huang S, Wang Z, Li J, Song X, Jiang Z Nat Commun. 2025; 16(1):1016.

PMID: 39863571 PMC: 11762306. DOI: 10.1038/s41467-025-56308-9.

Heterogeneity analysis and prognostic model construction of HPV negative oral squamous cell carcinoma T cells using ScRNA-seq and bulk-RNA analysis.

Li C, Lv Z, Li C, Yang S, Liu F, Zhang T Funct Integr Genomics. 2025; 25(1):25.

PMID: 39849233 PMC: 11759468. DOI: 10.1007/s10142-024-01525-6.

References

Reily C, Stewart T, Renfrow M, Novak J . Glycosylation in health and disease. Nat Rev Nephrol. 2019; 15(6):346-366. PMC: 6590709. DOI: 10.1038/s41581-019-0129-4. View

Ohtsubo K, Marth J . Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126(5):855-67. DOI: 10.1016/j.cell.2006.08.019. View

Dube D, Bertozzi C . Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4(6):477-88. DOI: 10.1038/nrd1751. View

Pinho S, Reis C . Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015; 15(9):540-55. DOI: 10.1038/nrc3982. View

van Kooyk Y, Rabinovich G . Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008; 9(6):593-601. DOI: 10.1038/ni.f.203. View

McCarthy C, Saldova R, Wormald M, Rudd P, McElvaney N, Reeves E . The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res. 2014; 13(7):3131-43. DOI: 10.1021/pr500146y. View

Rabinovich G, Croci D . Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 2012; 36(3):322-35. DOI: 10.1016/j.immuni.2012.03.004. View

Croci D, Cerliani J, DAlotto-Moreno T, Mendez-Huergo S, Mascanfroni I, Dergan-Dylon S . Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014; 156(4):744-58. DOI: 10.1016/j.cell.2014.01.043. View

Dewald J, Colomb F, Bobowski-Gerard M, Groux-Degroote S, Delannoy P . Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer. Cells. 2016; 5(4). PMC: 5187527. DOI: 10.3390/cells5040043. View

10.

Kirwan A, Utratna M, ODwyer M, Joshi L, Kilcoyne M . Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int. 2015; 2015:490531. PMC: 4609776. DOI: 10.1155/2015/490531. View

11.

Hanic M, Lauc G, Trbojevic-Akmacic I . N-Glycan Analysis by Ultra-Performance Liquid Chromatography and Capillary Gel Electrophoresis with Fluorescent Labeling. Curr Protoc Protein Sci. 2019; 97(1):e95. DOI: 10.1002/cpps.95. View

12.

Smith B, Bertozzi C . The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nat Rev Drug Discov. 2021; 20(3):217-243. PMC: 7812346. DOI: 10.1038/s41573-020-00093-1. View

13.

Cerliani J, Blidner A, Toscano M, Croci D, Rabinovich G . Translating the 'Sugar Code' into Immune and Vascular Signaling Programs. Trends Biochem Sci. 2016; 42(4):255-273. DOI: 10.1016/j.tibs.2016.11.003. View

14.

Toscano M, Martinez Allo V, Cutine A, Rabinovich G, Marino K . Untangling Galectin-Driven Regulatory Circuits in Autoimmune Inflammation. Trends Mol Med. 2018; 24(4):348-363. DOI: 10.1016/j.molmed.2018.02.008. View

15.

Girotti M, Salatino M, DAlotto-Moreno T, Rabinovich G . Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression. J Exp Med. 2019; 217(2). PMC: 7041721. DOI: 10.1084/jem.20182041. View

16.

Navarro P, Martinez-Bosch N, Blidner A, Rabinovich G . Impact of Galectins in Resistance to Anticancer Therapies. Clin Cancer Res. 2020; 26(23):6086-6101. DOI: 10.1158/1078-0432.CCR-18-3870. View

17.

Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

18.

Xu W, Huang Q, Huang A . Emerging role of galectin family in inflammatory autoimmune diseases. Autoimmun Rev. 2021; 20(7):102847. DOI: 10.1016/j.autrev.2021.102847. View

19.

Slack R, Mills R, Mackinnon A . The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2020; 130:105881. DOI: 10.1016/j.biocel.2020.105881. View

20.

Somogyi V, Chaudhuri N, Torrisi S, Kahn N, Muller V, Kreuter M . The therapy of idiopathic pulmonary fibrosis: what is next?. Eur Respir Rev. 2019; 28(153). PMC: 9488691. DOI: 10.1183/16000617.0021-2019. View